Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study

BACKGROUND: The outbreak of COVID-19 (caused by SARS-Cov-2) is very serious, and no effective antiviral treatment has yet been confirmed. The adage “old drug, new trick” in this context may suggest the important therapeutic potential of existing drugs. We found that the lopinavir/ritonavir treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xi, Chen, Huili, Shang, Yuqi, Zhu, Hongqiong, Chen, Gongqi, Chen, Yuanli, Liu, Shaoxuan, Zhou, Yaoyong, Huang, Mingxing, Hong, Zhongsi, Xia, Jinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341476/
https://www.ncbi.nlm.nih.gov/pubmed/32641091
http://dx.doi.org/10.1186/s13063-020-04478-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341476/
https://www.ncbi.nlm.nih.gov/pubmed/32641091
http://dx.doi.org/10.1186/s13063-020-04478-w

Ejemplares similares